. 2019 Jul 5;8(10):4938–4953. doi: 10.1002/cam4.1879

Table 2.

Multivariable Cox model for HPV‐16 newly detected infections and cervical abnormalities including serostatus at baseline

Risk factor	Category	Enrollment serostatus (binary)
		Incident infection				6‐mo PI				12‐mo PI				ASC‐US+
		N	n	Hazard ratio (95% CI)	P‐value	N	n	Hazard ratio (95% CI)	P‐value	N	n	Hazard ratio (95% CI)	P‐value	N	n	Hazard ratio (95% CI)	P‐value
HPV‐16 serostatus	Negative	1814	114	1	‐	1779	67	1	‐	1755	38	1	‐	1787	43	1	‐
HPV‐16 serostatus	Positive	790	45	0.81 (0.56‐1.16)	0.2559	767	17	0.56 (0.32‐0.99)	0.0446	753	8	0.53 (0.24‐1.16)	0.1123	774	9	0.28 (0.12‐0.67)	0.0043
Age at inclusion	26‐35	1157	94	1	‐	1134	45	1	‐	1109	21	1	‐	1139	33	1	‐
Age at inclusion	≥36	1157	65	0.58 (0.42‐0.82)	0.0016	1412	39	0.78 (0.50‐1.24)	0.2946	1399	25	0.99 (0.54‐1.82)	0.9817	1423	19	0.57 (0.31‐1.03)	0.0640
Region	Europe	505	22	1	‐	495	6	1	‐	491	5	1	‐	500	8	1	‐
	Asia Pacific	779	38	1.19 (0.68‐2.08)	0.5445	772	23	2.57 (1.01‐6.52)	0.0476	765	15	1.75 (0.61‐5.05)	0.3004	772	10	0.77 (0.28‐2.10)	0.6065
	Latin America	679	43	1.56 (0.90‐2.71)	0.1142	663	29	3.86 (1.54‐9.70)	0.0040	658	16	2.26 (0.79‐6.48)	0.1308	666	18	1.66 (0.65‐4.21)	0.2862
	North America	641	56	2.38 (1.42‐3.97)	0.0009	616	26	4.28 (1.74‐10.54)	0.0015	594	10	1.89 (0.63‐5.66)	0.2575	623	16	1.32 (0.50‐3.46)	0.5716
Age at first sexual intercourse grouped	≥18	1654	98	1	‐	1621	57	1	‐	1600	33	1	‐	1630	32	1	‐
	15‐17	817	50	0.85 (0.58‐1.23)	0.3775	799	57	0.62 (0.36‐1.09)	0.0967	784	9	0.56 (0.26‐1.22)	0.1473	804	14	1.05 (0.53‐2.08)	0.8832
	<15	127	11	1.08 (0.56‐2.07)	0.8271	120	8	1.48 (0.67‐3.27)	0.3329	118	4	1.30 (0.43‐3.95)	0.6433	121	6	2.20 (0.79‐6.16)	0.1322
Marital status at baseline	Living or lived with partner	2227	129	1	‐	2177	69	1	‐	2151	41	1	‐	2190	44	1	‐
Marital status at baseline	Single	377	30	0.79 (0.49‐1.29)	0.3493	369	15	0.89 (0.46‐1.75)	0.7434	357	5	0.70 (0.24‐2.04)	0.5116	371	8	0.67 (0.27‐1.67)	0.3878
Smoking status at baseline	No	2264	131	1	‐	2221	72	1	‐	2192	40	1	‐	2229	40	1	‐
Smoking status at baseline	Yes	340	28	1.35 (0.88‐2.06)	0.1701	325	12	1.15 (0.61‐2.17)	0.6678	316	6	1.10 (0.45‐2.70)	0.8278	332	12	1.78 (0.89‐3.59)	0.1049
Number of sexual partners during the last year	0	283	16	1	‐	277	8	1	‐	272	2	1	‐	279	5	1	‐
	1	2096	112	0.88 (0.52‐1.52)	0.6563	2052	59	1.02 (0.48‐2.18)	0.9634	2026	35	2.26 (0.54‐9.57)	0.2663	2064	36	0.89 (0.33‐2.35)	0.8105
	≥2	225	31	2.36 (1.26‐4.44)	0.0074	217	17	3.53 (1.47‐8.48)	0.0048	210	9	8.20 (1.70‐39.49)	0.0087	218	11	1.72 (0.56‐5.28)	0.3399
Pregnancy	No	401	35	1	‐	393	19	1	‐	384	7	1	‐	394	11	1	‐
Pregnancy	Yes	2203	124	0.74 (0.47‐1.14)	0.1732	2153	65	0.57 (0.31‐1.05)	0.0696	2124	39	0.82 (0.33‐2.06)	0.6793	2167	41	0.91 (0.40‐2.06)	0.8211
Chlamydia infection at baseline	No	2458	150	1	‐	2407	81	1	‐	2371	44	1	‐	2420	48	1	‐
Chlamydia infection at baseline	Yes	122	7	0.59 (0.27‐1.29)	0.1848	115	2	0.36 (0.08‐1.51)	0.1618	113	2	0.95 (0.21‐4.32)	0.9486	117	3	2.57 (0.71‐9.27)	0.1483
History of HPV infection/treatment or not intact cervix	No	2285	128	1	‐	2234	72	1	‐	2202	39	1	‐	2246	3	1	‐
History of HPV infection/treatment or not intact cervix	Yes	319	31	1.56 (1.03‐2.35)	0.0348	312	12	1.17 (0.62‐2.18)	0.6316	306	7	1.31 (0.57‐3.02)	0.5240	315	8	1.03 (0.45‐2.36)	0.9416
Previous HPV‐16 infection	No			‐	‐			‐	‐			‐	‐	2561	24	1	‐
Previous HPV‐16 infection	Yes			‐	‐			‐	‐			‐	‐	128	28	122.89 (67.91‐222.37)	<.0001

HPV = human papillomavirus; PI = persistent infection; CI = confidence interval; ACS‐US+ = atypical squamous cell of undetermined significance or greater; N = total number of subjects; n = number of cases reported. Bold: P‐values <0.05